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Abstract
Background: Type 2 diabetes (T2DM) is a burdensome condition for individuals to live with and an increasingly costly
condition for health services to treat. Cost-effective treatment strategies are required to delay the onset and slow the
progression of diabetes related complications. The Diabetes Telephone Coaching Study (DTCS) demonstrated that
telephone coaching is an intervention that may improve the risk factor status and diabetes management
practices of people with T2DM. Measuring the cost effectiveness of this intervention is important to inform
funding decisions that may facilitate the translation of this research into clinical practice. The purpose of this
study is to assess the cost-effectiveness of telephone coaching, compared to usual diabetes care, in participants
with poorly controlled T2DM.
Methods: A cost utility analysis was undertaken using the United Kingdom Prospective Diabetes Study
(UKPDS) Outcomes Model to extrapolate outcomes collected at 6 months in the DTCS over a 10 year time
horizon. The intervention’s impact on life expectancy, quality-adjusted life expectancy (QALE) and costs was
estimated. Costs were reported from a health system perspective. A 5 % discount rate was applied to all future
costs and effects. One-way sensitivity analyses were conducted to reflect uncertainty surrounding key input
parameters.
Results: The intervention dominated the control condition in the base-case analysis, contributing to cost
savings of $3327 per participant, along with non-significant improvements in QALE (0.2 QALE) and life
expectancy (0.3 years).
Conclusions: The cost of delivering the telephone coaching intervention continuously, for 10 years, was fully
recovered through cost savings and a trend towards net health benefits. Findings of cost savings and net health
benefits are rare and should prove attractive to decision makers who will determine whether this intervention is
implemented into clinical practice.
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Background
Considerable economic burden is imposed by type 2 dia-
betes (T2DM) [1], which is increasing in prevalence. In-
terventions that improve risk factor status and clinical
guideline adherence may prevent complications and re-
duce the healthcare costs associated with T2DM. Given
the wide array of interventions for the management of
T2DM, decisions to fund and implement these should
be informed by estimates of both efficacy and cost-
effectiveness. This ensures that patients are provided
with treatments that represent the optimal use of scarce
resources.
There is growing interest in telephone coaching inter-
ventions for people with T2DM. As suggested by the
Diabetes Telephone Coaching Study (DTCS) [2], these
interventions may to improve the risk factor status and
diabetes management practices of people with T2DM.
The DTCS recruited 94 participants with poorly con-
trolled T2DM (HbA1C greater than 7 %) from the
Diabetes Clinic at St Vincent’s Hospital Melbourne, an
Australian tertiary hospital. Participants were rando-
mised to usual care plus telephone coaching, or usual
care alone for 6 months. Follow up occurred at 6 months
(the end of the intervention period) and at 12 months
(6 months after withdrawal of the intervention).
Diabetes coaching in this study was defined as the
regular provision of telephone advice and coaching that
addressed lifestyle modification, adherence to treatment
schedules, goal setting and barriers to change. Specific-
ally, monthly coaching sessions were delivered by a
dietitian. Participants were encouraged to make changes
to their diet and exercise habits; to discuss specific medi-
cation changes with their general practitioner (GP), and
to adhere to the recommended schedule for foot checks,
eye checks and vaccinations. Relevant goals were agreed
upon at each coaching session and progress towards goal
attainment was reviewed at subsequent coaching ses-
sions. If goals were not achieved, barriers to goal attain-
ment were identified and a plan that addressed these
barriers was agreed. New goals were set as required.
This process was repeated throughout the intervention.
The primary outcome, HbA1C at 6 months, was sig-
nificantly lower among the intervention group compared
to the controls, −0.8 %, 95 % confidence interval (CI)
(−1.2 to −0.3) [2]. Other parameters that improved at
6 months included fasting glucose, diastolic blood pres-
sure, physical activity and adherence to diabetes man-
agement practices. However, improvements observed at
6 months were not sustained at 12 months.
Although the DTCS did not show sustained benefits
upon withdrawal of the coaching, numerous trials have
indicated that the provision of ongoing follow-up and
support facilitates the longer-term maintenance of inter-
vention gains [3–12]. These trials strongly support the
notion that if the telephone coaching was delivered on
an ongoing basis, improvements observed at 6 months
in the DTCS are likely to be maintained.
Extrapolating from the results of the DTCS, the present
analysis sought to assess the cost-effectiveness of tele-
phone coaching for patients with T2DM. While many
telephone coaching trials have speculated regarding the
potential cost-effectiveness of these interventions, few
have measured changes in resource use [26, 45, 46], and
fewer still have assessed cost-effectiveness [47, 48]. This is
the first Australian study to assess the cost-effectiveness of
telephone coaching in a population exclusively with
T2DM. Measuring costs in an Australian context is im-
portant due to international differences in healthcare costs
[13, 14]. Importantly, estimates of cost-effectiveness are
relevant to funding decisions that facilitate the translation
of research evidence into clinical practice.
Methods
A cost utility analysis was undertaken to compare tele-
phone coaching with usual care. Six-month outcome
data from the DTCS were applied to the UKPDS Out-
comes Model in order to predict marginal changes in
risks of clinical events (myocardial infarction [MI], cor-
onary heart disease [CHD], stroke, congestive heart fail-
ure [CHF], amputation, renal failure and blindness),
years lived, quality-adjusted life years (QALYs) lived and
costs. The analysis took a health system perspective,
considering direct healthcare costs met by the Victorian
State and Commonwealth Governments.
It was assumed that intervention group participants
received telephone coaching for 10 years, with interven-
tion costs maintained during each year that participants
were predicted to survive. Although other telephone
coaching trials have observed improved glycaemic con-
trol with 12 months of intervention [9, 15–20], and the
maintenance literature indicates that the provision of
ongoing follow-up and support facilitates the longer-
term maintenance of intervention gains [3–12], the true
effect of continuously delivering this intervention
remains uncertain. Consequently, conservative assump-
tions were made concerning the impact of the interven-
tion on HbA1C. Rather than assuming that HbA1C
values observed at 6 months in the DTCS were main-
tained throughout the modelled time horizon, HbA1C
values in each simulation year were predicted by the
UKPDS model. Sensitivity analyses were also conducted
to account for this uncertainty.
In the base-case analysis, a 5 % discount rate was ap-
plied to all future costs and benefits. This rate was var-
ied in the sensitivity analyses to reflect uncertainty. A
10 year time horizon was chosen for the base-case ana-
lysis. This was varied in the sensitivity analyses to two,
five and 15 years. The primary outcome was an
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incremental cost-effectiveness ratio (ICER), expressed as
a cost per QALY saved.
The UKPDS Outcomes Model is a probabilistic,
discrete-time computer simulation model that uses algo-
rithms based on UKPDS data to predict the develop-
ment of seven diabetes-related complications (MI, CHD,
stroke, CHF, amputation, renal failure and blindness)
and death. The model enables economic evaluations of
interventions that affect risk factors in people with
T2DM [21]. In the present analysis, model subjects com-
prised participants of the DTCS, who entered the model
with characteristics based on levels at the end of the six
month intervention period. Missing data at 6 months
were imputed using the last observation carried forward
method, with values observed at baseline used to impute
missing values at 6 months. The model also demands
data concerning the risk factor status of participants at
diagnosis of T2DM. This information was not available
to investigators, therefore, it was assumed that these
levels were the same as those recorded at the partici-
pant’s baseline assessment in the DTCS. The model ran
in one year cycles, for which the risks of complications
and death were predicted. Predictions were made based
on each participant’s six month characteristics and risk
factors that the model changed with time. The model
accounted for event-related dependencies, whereby the
presence of one complication (such as CHD) increased
the likelihood of another (such as CHF) and furthermore
increased the risk of death. Participants continued
through the model for 10 cycles, or until death.
Key model inputs are summarised in the Additional file
1. Health utility values were updated following each model
cycle and used to calculate QALYs at the end of the simula-
tion period. Multiple complications were assumed to have
an additive effect on quality of life. The health utility values
assigned to participants were based on UKPDS data [22].
Costs were reported in 2012/13 Australian dollars.
Costs were deflated to their net present value using the
Health Price Index [23]. The model applied acute and
ongoing costs to events predicted to develop in the
simulation period. These costs were sourced from Aus-
tralian data [24].
A cost was also applied to participants without diabetes-
related complications. This cost reflected diabetes-related
costs incurred by DTCS participants between baseline and
6 months of the study, and thus considered the cost of
medications, general practitioner presentations, St Vin-
cent’s Hospital outpatient appointments, St Vincent’s
Hospital emergency department presentations and St Vin-
cent’s Hospital inpatient admissions. This six monthly cost
was multiplied by a factor of two to estimate annual costs.
To account for the cost of the telephone coaching
intervention, an annual discounted cost was applied to
intervention group participants ‘post-hoc’. This reflected
staffing and telephone call costs and was added to the
cost of intervention group participants during each
simulation year they were predicted to survive. One-way
sensitivity analyses were conducted to reflect uncertainty
surrounding key input parameters (Table 1).
All procedures followed in this study complied with
requirements of the St Vincent’s Hospital Human Re-
search Ethics Committee.
Results
The groups were balanced at entry into the model with
the exception of HbA1C levels, these being lower in the
intervention group, 7.8 % versus 8.7 %, p = 0.003 (reflect-
ing the efficacy of the intervention delivered in the
DTCS). In addition, intervention group participants were
less commonly Asian/Indian and more commonly Cau-
casian. The groups differed in the number of years since
they had suffered a stroke (Table 2). This difference
reflected a finding from the DTCS showing that fewer
intervention group participants had previously suffered a
stroke, nil versus 8 (17 %). Based on data collected be-
tween baseline and 6 months of the DTCS, annual costs
were applied to participants in each group to reflect the
annual cost of treating participants without diabetes-
related complications. The mean (95 % CI) costs applied
to intervention and control group participants were
$6091 (2183–9998) and $3107 (2530–3683), respectively.
To reflect the cost of delivering the telephone coaching
intervention, a cost of $1286 was applied to intervention
group participants during each simulation year they
were predicted to survive.
Over 10 years, the model predicted that the interven-
tion would dominate the comparator, contributing to
Table 1 Parameters varied in sensitivity analyses
Key input parameter Sensitivity analyses
Time horizon Five, 15, 20 years
Discount rate 3 %, 4 %, 6 % to future costs and effects
Health utilities Varied according to the upper and lower
limits of the 95 % CI surrounding mean
values reported by Clarke and colleagues
(Clarke et al., 2002)
Cost of complications Varied according to the upper and lower
limits of the 95 % CI surrounding mean
values reported by Clarke and colleagues
(Clarke et al., 2008)
Cost in the absence of
complications
Varied according to the upper and lower
limits of the 95 % CI surrounding mean
values reported in DTCS.
HbA1C Assumed that HbA1C at 6 months in the
DTCS was maintained for one, two and five
simulation years.
Stroke Assumed that no participants had a past
history of stroke.
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net health benefits at a lower cost. The intervention con-
tributed to savings of over $3300 per participant and an
incremental gain of 0.2 QALYs. Ten year discounted
costs were $59,790 and $63,117 among intervention ver-
sus control group participants, respectively, while 4.88
and 4.68 discounted QALYs were lived by the two
groups. The intervention contributed to an incremental
gain in life expectancy of 0.3 years (Table 3). The model
predicted that the between-group difference in HbA1C
at entry into the model reduced over time (Fig. 1). There
was a trend toward higher health utility scores and lower
annual treatment costs among intervention group partic-
ipants (Fig. 2a and b).
Table 4 summarises the cumulative incidence of first
events among participants in each group over 10 years.
The 10 year risk of any complication was lower in the
intervention group, 32 % versus 38 %. The risk of death
was also lower among intervention group participants,
Table 2 Characteristics of the simulated population
Intervention group, n = 47 Control group, n = 47 Total, n = 94 P-value
Demographic characteristics
Ethnicity, n (%) Caucasian 46 (98) 37 (79) 83 (88) 0.02
Afro-Caribbean 0 (2) 2 (4) 2 (2)
Asian/Indian 1 (2) 8 (17) 9 (10)
Gender, n (%) Male 34 (72 %) 30 (64 %) 64 (68) 0.51
Female 13 (28 %) 17 (36 %) 30 (32)
Age at diagnosis (years) 47 (44–50) 50 (47–53) 48 (46–51) 0.13
Diabetes duration (years) 13 (10–15) 13 (11–16) 13 (11–15) 0.75
Risk factor values at diagnosis of T2DM
AF, n (%) 1 (2) 0 (0) 1 (2) 1.00
Peripheral vascular disease n (%) 0 (0) 2 (4) 2 (4) 0.5
Smoking n (%) Current smoker 18 (38) 17 (36) 35 (37) 0.57
Never smoker 21 (45) 25 (53) 46 (49)
Ex-smoker 8 (17) 5 (11) 13 (14)
Cholesterol (mmol/l) 4.1 (3.9–4.4) 4.5 (4.1–4.9) 4.3 (4.0–4.5) 0.15
High density lipoprotein (mmol/l) 1.1 (1.0–1.2) 1.2 (1.1–1.2) 1.1 (1.1–1.2) 0.42
Systolic blood pressure (mmHg) 140 (134–145) 134 (128–140) 137 (133–141) 0.13
HbA1c (%) 8.2 (8.0–9.7) 8.5 (8.1–8.9) 8.3 (8.1–8.6) 0.18
Risk factor values at entry into the model
(6 months in the DTCS)
Smoking, n (%) Current smoker 5 (11) 8 (17) 13 (14) 0.3
Never smoker 21 (45) 25 (53) 46 (49)
Ex-smoker 21 (45) 14 (29) 35 (37)
Cholesterol (mmol/l) 4.0 (3.8–4.3) 4.5 (4.0–4.9) 4.3 (4.0–4.5) 0.07
High density lipoprotein (mmol/l) 1.1 (1.0–1.1) 1.2 (1.1–1.2) 1.1 (1.1–1.2) 0.12
Systolic blood pressure (mmHg) 133 (128–138) 132 (127–138) 133 (129–136) 0.9
HbA1C (%) 7.8 (7.4–8.1) 8.7 (8.2–9.2) 8.2 (7.9–8.5) 0.003
Years since pre-existing event
CHD (excluding MI) 0.8 (0.0–1.6) 1.3 (0.2–2.4) 1.1 (0.4–1.7) 0.45
CHF 0.1 (0.0–0.3) 0.3 (0.0–0.6) 0.2 (0.0–0.4) 0.32
Amputation 0.1 (0.0–0.2) 0.0 (0.0–0.1) 0.1 (0.0–0.1) 0.4
Blindness 0.5 (0.0–1.1) 0.1 (0.0–0.3) 0.3 (0.0–0.6) 0.15
Renal failure 0.2 (0.2–0.6) 0.3 (0.0–0.5) 0.3 (0.0–0.5) 0.71
Stroke 0.0 (0.0–0.1) 1.3 (0.2–2.4) 0.7 (0.1–1.2) 0.03
MI 1.2 (0.3–2.2) 2.7 (0.4–5.0) 1.9 (0.7–3.2) 0.25
All results presented as mean (95 % CI) unless otherwise specified. P values in bold < 0.05 and considered statistically significant
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32 intervention group participants predicted to survive
for 10 years compared to 30 controls.
The intervention dominated the control condition
under most conditions tested in sensitivity analyses. The
largest savings were observed when the treatment costs
of participants without complications were adjusted to
reflect the lower limit of the 95 % CI surrounding this
value (Table 5).
Discussion
The results of these analyses suggest that the cost of
investing in telephone coaching would be fully recovered
through cost savings over 10 years. Treatment costs
were $3327 lower among intervention group partici-
pants. Savings were driven by lower costs associated
with treating diabetes-related complications; the cost of
treating these was almost $12,000 lower per intervention
group participant. Intervention group participants also
gained an additional 0.20 QALYs and 0.3 years of life
over 10 years. Like cost savings, improvements in QALE
and life expectancy were driven by reductions in the risk
of complications. The 10 year risk of MI, CHF, any com-
plication and death was lower among intervention group
participants, with risk reductions of 24, 20, 13 and 16 %
observed. Given that the DTCS was powered for the
primary endpoint of change in HbA1C, it is likely that a
much larger sample size would be required to demon-
strate statistical significance for the economic analysis.
Nevertheless, an intervention which would save over
$3000 per patient over 10 years would result in substan-
tial cost reductions across the health care system, even if
the clinical endpoints were neutral.
Predicted cost savings and net health benefits were ap-
parent despite conservative assumptions concerning the
intervention’s cost and its impact on glycaemic control.
For instance, rather than assuming that HbA1C levels at
6 months in the DTCS were sustained in subsequent
simulation years, trends in HbA1C were predicted by
the model. Consequently, glycaemic control was pre-
dicted to deteriorate in both groups over time. Costs
were also applied conservatively, with higher annual
treatment costs applied to the intervention group to ac-
count for the cost of the telephone coaching interven-
tion and other treatment costs that were higher in this
group during the trial. Having applied these conservative
assumptions, confidence in the validity of this study’s
findings is further enhanced.
Also enhancing confidence in the validity were results
showing that predictions of cost savings were robust to
most conditions tested in the sensitivity analyses. The
Table 3 Findings from the base-case analysis
Intervention group, n = 47 Control group, n = 47 Difference
Life expectancy (years) 8.1 7.7 0.3
Total QALE 4.9 4.7 0.2
Cost of the intervention ($) 8581 0 8581
Cost of complications ($) 51,210 63,117 −11,907
Total cost ($) 59,790 63,117 −3327
ICER intervention dominated the control condition






















Fig. 1 Change in mean (95 % CI) HbA1C over 10 years
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greatest cost savings were observed when cost of treating
participants without diabetes-related complications was
adjusted to reflect the lower limit of the 95 % CI sur-
rounding this value. However, cost savings disappeared
when past history of stroke was controlled for, suggest-
ing that this chance imbalance between the groups may
have biased findings in favour of the intervention group.
However, at a cost of $4365 per QALY, the intervention
was considered highly cost-effective under this condition
and therefore, should still prove attractive to decision
makers considering whether this intervention should be


















































Fig. 2 a Predicted change in mean (95 % CI) health utility over 10 years, and b Predicted change in mean (95% CI) cumulative costs over 10 years
Table 4 Mean (95 % CI) cumulative incidence of first events over 10 years
Intervention group, n = 47 Control group, n = 47
Cumulative incidence Number of cases Cumulative incidence Number of cases
CHD 0.05 2 0.05 2
MI 0.13 6 0.17 8
CHF 0.04 2 0.05 2
Stroke 0.05 2 0.05 2
Amputation 0.02 1 0.02 1
Blindness 0.02 1 0.03 1
Renal failure 0.02 1 0.01 0
Any complication 0.32 15 0.38 18
Diabetes-related death 0.12 6 0.17 7
All death 0.36 15 0.43 17
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Table 5 Findings from the sensitivity analyses
Quality adjusted life expectancy (QALYs) Direct healthcare costs (2012/13 Australian dollars) ICER
(Cost per QALY)
Intervention
group (n = 47)
Control
group (n = 47)
Difference Intervention




Base-case 4.9 (4.5–5.2) 4.7 (4.4–5.0) 0.2 (0–0.3) 59,790 (48,182–71,399) 63,117 (41,490–84,745) −3327 (−27,645–20,991) Dominant
Time horizon Two years 1.4 (1.3–1.4) 1.4 (1.3–1.4) 0.0 (−0.1–0.1) 16,581 (12,619–20,543) 20,440 (12,436–28,445) −3859 (−12,715–4997) $3859 saved
Nil benefit
Five years 3.1 (2.9–3.2) 3.0 (2.8–3.1) 0.1 (−0.2–0.3) 36,801 (28,599–45,003) 41,562 (26,330–56,795) −4761 (−21,901–12,378) Dominant
15 years 6.9 (6.2–7.5) 6.5 (5.8–7.1) 0.4 (−0.5–1.3) 85,014 (70,189–99,838) 85,124 (57,566–112,681) −110 (−31,111–30,890) Dominant
Discount rate 0 % 6.2 (5.8–6.7) 5.9 (5.5–6.4) 0.3 (−0.3–0.9) 73,839 (59,390–88,288) 78,987 (52,235–105,739) −5148 (−35,268–24,972) Dominant
3 % 5.4 (5.0–5.7) 5.2 (4.8–5.5) 0.2 (−0.3–0.8) 65,125 (52,499–77,750) 68,797 (45,334–92,261) −3673 (−30,070–22,724) Dominant
6 % 4.7 (4.4–5.0) 4.5 (4.2–4.8) 0.2 (−0.3–0.6) 56,800 (45,654–67,946) 60,556 (39,758–81,354) −3756 (−27,134–19,622) Dominant
Utility scores Lower limit of 95 % CI 4.8 (4.5–5.2) 4.6 (4.3–5.0) 0.2 (−0.3–0.7) 59,790 (48,182–71,399 63,117 (41,490–84,745) −3327 (−27,645–20,991) Dominant
Upper limit of 95 % CI 4.9 (4.6–5.2) 4.7 (4.4–5.0) 0.2 (−0.3–0.7) 59,790 (48,182–71,399 63,117 (41,490–84,745) −3327 (−27,645–20,991) Dominant
Cost of complications Lower limit of 95 % CI 4.9 (4.5–5.2) 4.7 (4.4–5.0) 0.2 (0–0.3) 53,979 (45,646–62,311) 52,493 (36,526–68,460) 1485 (−16,285–19,256) $7425 per
QALY
Upper limit of 95 % CI 4.9 (4.5–5.2) 4.7 (4.4–5.0) 0.2 (0–0.3) 66,455 (51,397–81,513) 74,526 (47,419–101,633) −8071 (−38,667–22,524) Dominant
Cost – no complications Lower limit of 95 % CI 4.9 (4.5–5.2) 4.7 (4.4–5.0) 0.2 (−0.3–0.7) 45,347 (32,674–58,020) 61,116 (39,199–83,034) −15,769 (−40,833–9294) Dominant
Upper limit of 95 % CI 4.9 (4.7–5.1) 4.7 (4.4–4.9) 0.2 (−0.3–0.7) 74,261 (62,640–85,881) 65,139 (43,796–86,483) 9121 (−14,951–33,194) $45,605 per
QALY
HbA1C HbA1C maintained for
one simulation year
4.9 (4.7–5.1) 4.7 (4.4–4.9) 0.2 (−0.3–0.7) 59,931 (48,276–71,586) 63,214 (41,475–84,953) −3283 (−27,721–21,155) Dominant
HbA1C maintained for
two simulation years
4.9 (4.7–5.1) 4.7 (4.4–4.9) 0.2 (−0.3–0.7) 59,986 (48,307–71,665) 62,628 (41,116–84,140) −2642 (−26,890–21,606) Dominant
HbA1C maintained for
five simulation years
4.9 (4.7–5.1) 4.7 (4.4–4.9) 0.2 (−0.3–0.7) 60,014 (48,343–71,685) 62,974 (41,251–84,696) −2960 (−27,390–21,470) Dominant
Stroke Nil past history of stroke
in either group
4.9 (4.5–5.2) 4.7 (4.3–5.0) 0.2 (−0.3–0.7) 59,134 47,497–70,771 58,261 (38,557–77,966) 873 (−21,778–23,523) $4365 per
QALY














Only one Australian study was identified as having
assessed the cost-effectiveness of a telephone delivered,
behaviour change counselling intervention in people
with T2DM. The analysis drew upon data from a rando-
mised controlled trial (RCT) which found that a
12 month telephone coaching intervention contributed
to significant improvements in diet but not physical ac-
tivity in participants with T2DM or hypertension [25].
Modelled over 10 years and compared with usual care,
the intervention was not cost-effective, however, com-
pared with existing practice, the intervention was con-
sidered cost-effective at a cost of $29,375 per QALY
gained [26]. Investigators in this study differentiated
existing practice from usual care, noting that partici-
pants receiving usual care received more intervention
(telephone calls for data collection, verbal feedback on
dietary and exercise behaviour and written education
material) than was typical under existing practice
conditions.
The present economic analysis might be differentiated
from that of Graves and colleagues in a number of
respects. For instance, the RCT on which Graves and
colleagues’ economic analysis was based, recruited par-
ticipants with either T2DM or hypertension [25]. There-
fore, projections of costs and effects do not relate
specifically to people with T2DM. Furthermore, the
study extrapolated outcomes observed at 12 months in
the RCT (namely the intervention’s impact on physical
activity) to predict cost-effectiveness over 10 years [25].
However, physical activity is less reliable as a marker of
long-term outcomes in T2DM than HbA1C. Whereas
prospective RCTs demonstrate a cause and effect rela-
tionship between HbA1C, morbidity and mortality (key
drivers of costs and effects in people with T2DM), evi-
dence concerning the impact of physical activity on such
endpoints comes from epidemiological and cohort stud-
ies [27–30]. Therefore, the present economic analysis
may provide a more reliable estimate concerning the
cost-effectiveness of telephone coaching in people with
T2DM.
No other telephone coaching trials were identified as
having contributed to both cost savings and net health
benefits in people with T2DM. However, comparison of
findings from the present economic analysis with other
telephone coaching studies is difficult, firstly, because
most were conducted in other countries and secondly,
because of methodological issues that limit the validity
and generalisability of their findings. For instance, one
study expressed the ICER as a cost per unit change in a
surrogate endpoint [31], another measured only costs
[32] and several conducted only within-trial economic
analyses, failing to project outcomes over a sufficient
time horizon to facilitate valid comparison with findings
from this economic analysis [31–35]. Comparison with
results from other countries is invalid owing to inter-
national differences in health systems and healthcare
costs [13, 14]. Therefore, this economic analysis makes a
valuable contribution to knowledge concerning the cost-
effectiveness of telephone coaching in Australians with
T2DM.
As with all modelling analyses, a degree of uncertainty
surrounds predictions obtained through the extrapola-
tion of data from a short-term clinical trial that never
empirically assessed the intervention’s impact on sur-
vival, event rates, costs or QALE. For instance, confound-
ing may have been present due to the age difference
between the intervention and comparator groups, but
having randomised the groups in the original study, this is
unlikely to have changed the conclusion that the DTCS
would likely be highly cost-effective. Longer, prospective
RCTs are required to validate predictions obtained in this
study. Simulation models provide a parsimonious solution
to the absence of such long-term prospective data and
despite their limitations, are widely used to extrapolate
outcomes beyond the conclusion of clinical trials. Having
applied conservative assumptions, the best available simu-
lation model and extensive sensitivity analyses, the validity
of findings from this study might be enhanced. As our evi-
dence is indirect, caution should be taken in interpreting
the results.
Limitations also relate to the UKPDS Outcomes
Model. Previous studies have indicated that this model
over-estimates event rates and mortality risk in popula-
tions dissimilar to the one on which it was developed
[36, 37]. The model has not been validated for use in an
Australian population which is multicultural. Further-
more, the model predicts only a limited range of compli-
cations and predicts only first, not subsequent events
[21]. However, given that no other simulation models
have been validated for Australian populations, this
model was considered the best available for the purpose
of this economic analysis [38].
Other limitations relate to the measurement of costs
and effects. Consistent with a health system perspective,
only direct diabetes-related costs were considered.
Therefore, societal costs (to individuals and carers
through lost time, income and productivity) were not
captured. In terms of effects, utility weights applied in
this study were not determined empirically, but were in-
stead sourced from the literature. It is likely that these
values would differ from those that would be obtained
had DTCS participants been surveyed directly.
Findings from this analysis should be considered trans-
ferable to Australians with long-standing, T2DM that is
sub-optimally controlled. This population is substantial;
self-reported data from 2007 to 08 have indicated that
3.8 % of Australians (787,500 people) are affected by
T2DM [39] and observational data have indicated that
Varney et al. BMC Health Services Research  (2016) 16:521 Page 8 of 10
poor glycaemic control is common among Australians
with T2DM [40–43].
Conclusions
Interest in diabetes coaching interventions is growing,
with numerous such studies listed on the Australian
New Zealand Clinical Trials Registry, many of which are
collecting real-time, cost-effectiveness data. The RCT on
which the present economic analysis was based found
that adding a six month telephone coaching intervention
to the usual care regimen of participants with poorly
controlled T2DM led to improvements in glycaemic
control and a range of other parameters. This economic
analysis has shown that under conditions of the base-
case analysis and most sensitivity analyses, the interven-
tion would contribute to net health benefits and cost
savings. In assessing cost-effectiveness, this study has ex-
tended findings from the existing telephone coaching lit-
erature. Two sensitivity analyses did not predict cost
savings, instead predicting that the intervention would
be highly cost-effective at a cost of less than $10,000 per
QALY. It has previously been stated that dominant in-
terventions and interventions that cost less than $10,000
per QALY should only be ignored if ‘decision-makers
have very serious reservations about the evidence base
or are facing insurmountable problems in relation to
stakeholder acceptability or feasibility of implementation’
[44]. Findings from this study support the need for a
longer, prospective multi-centre trial of telephone coach-
ing to confirm both the clinical and economic benefits
prior to implementation into routine clinical practice.
Future research should also consider alternative coach-
ing delivery methods, using online and mobile inter-
active tools.
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